Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Authors: Davids, Matthew S. ^{1, ∗}, Ambrose, Jacob ², de Nigris, Enrico ³, Prescott, Jennifer ⁵, Leng, Siyang ⁴, Farooqui, Mohammed Z. H. ⁴, Gandra, Shravanthi R. ⁶, Zettler, Christina M. ², Fernandes, Laura L. ², Wang, Ching Kun ², Shadman, Mazyar ⁷

Source: In Blood Neoplasia February 2025 2(1)

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells

Authors: Baskar, Sivasubramanian ¹, Peng, Haiyong ², Gaglione, Erika M. ^{1, 3}, Carstens, Elizabeth J. ¹, Lindorfer, Margaret A. ³, Ahn, Inhye E. ¹, Herman, Sarah E. M. ¹, Skarzynski, Martin ¹, Chang, Jing ², Keyvanfar, Keyvan ¹, Butera, Vicent ¹, Blackburn, Amy ¹, Vire, Bérengère ¹, Maric, Irina ⁴, Stetler-Stevenson, Maryalice ⁵, Yuan, Constance M. ⁵, Eckhaus, Michael A. ⁶, Soto, Susan ¹, Farooqui, Mohammed Z. H. ¹, Taylor, Ronald P. ^{3, ∗∗∗}, Rader, Christoph ^{2, ∗∗}, Wiestner, Adrian ^{1, ∗}

Source: In Blood November 2024

Mapping of uncontrolled dumpsites in arid regions through remote sensing and image processing.

Authors: Al-Harbi, Mohamed, Tawabini, Bassam, Al-Farhan, Mohammed, Soupios, Pantelis, Farooqui, Mohammed, Basaleh, Abdullah

Source: Waste Management & Research: The Journal for a Sustainable Circular Economy; Apr2025, Vol. 43 Issue 4, p616-624, 9p

Subject Terms: IMAGE recognition (Computer vision), SPECTRAL reflectance, REMOTE sensing, REMOTE-sensing images, IMAGE processing

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Authors: Gregory, Gareth P. ^*, Kumar, Shaji, Wang, Ding, Mahadevan, Daruka, Walker, Patricia, Wagner-Johnston, Nina, Escobar, Carolina, Bannerji, Rajat, Bhutani, Divaya, Chang, Julie, Hernandez-Ilizaliturri, Francisco J., Klein, Andreas, Pagel, John M., Rybka, Witold, Yee, Andrew J., Mohrbacher, Anne, Huang, Mo, Farooqui, Mohammed, Marinello, Patricia, Quach, Hang

Source: In Blood Advances 22 February 2022 6(4):1232-1242

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

Authors: Andre, Thierry ^*, Amonkar, Mayur, Norquist, Josephine M, Shiu, Kai-Keen, Kim, Tae Won, Jensen, Benny Vittrup, Jensen, Lars Henrik, Punt, Cornelis J A, Smith, Denis, Garcia-Carbonero, Rocio, Sevilla, Isabel, De La Fouchardiere, Christelle, Rivera, Fernando, Elez, Elena, Diaz, Luis A, Jr, Yoshino, Takayuki, Van Cutsem, Eric, Yang, Ping, Farooqui, Mohammed, Le, Dung T

Source: In The Lancet Oncology May 2021 22(5):665-677

Healthcare resource utilization and costs of chronic lymphocytic leukemia/small lymphocytic lymphoma patients who relapse or are refractory to ibrutinib.

Authors: De Nigris, Enrico, Yang, Xiaoqin, Zanardo, Enrico, Lejeune, Dominique, Farooqui, Mohammed ZH, Gandra, Shravanthi R, Laliberté, François

Source: Future Oncology; 2024, Vol. 20 Issue 35, p2723-2735, 13p

Using artificial intelligence tools in answering important clinical questions: The KEYNOTE-183 multiple myeloma experience

Authors: Liao, Jason J.Z., Farooqui, Mohammed Z.H., Marinello, Patricia, Hartzel, Jonathan, Anderson, Keaven, Ma, Junshui, Gause, Christine K.

Source: In Contemporary Clinical Trials December 2020 99

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Authors: Sun, Clare ¹, Nierman, Pia ¹, Kendall, Ellen K. ¹, Cheung, Jean ⁴, Gulrajani, Michael ⁴, Herman, Sarah E.M. ¹, Pleyer, Christopher ¹, Ahn, Inhye E. ¹, Stetler-Stevenson, Maryalice ², Yuan, Constance M. ², Maric, Irina ³, Gaglione, Erika M. ¹, Harris, Hailey M. ¹, Pittaluga, Stefania ², Wang, Min Hui ⁴, Patel, Priti ⁴, Farooqui, Mohammed Z.H. ¹, Izumi, Raquel ⁴, Hamdy, Ahmed ⁴, Covey, Todd ⁴, Wiestner, Adrian ^{1, 1}

Source: In Blood 2 July 2020 136(1):93-105

The C-terminal tails of the mitochondrial transcription factors Mtf1 and TFB2M are part of an autoinhibitory mechanism that regulates DNA binding

Authors: Basu, Urmimala, Mishra, Nandini, Farooqui, Mohammed, Shen, Jiayu, Johnson, Laura C., Patel, Smita S.

Source: In Journal of Biological Chemistry 15 May 2020 295(20):6823-6830

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Authors: Nicol, Andrew, Grigoriadis, George, Catalano, John, LeBlanc, Richard, Elemary, Mohamed, Bahlis, Nizar, Facon, Thierry, Karlin, Lionel, Ribrag, Vincent, Attal, Michel, Goldschmidt, Hartmut, Engelhardt, Monika, Weisel, Katja, Mackensen, Andreas, Nagler, Arnon, Ben Yehuda, Dina, Avivi, Irit, Benyamini, Noam, Magen-Nativ, Hila, Palumbo, Antonio, Cavo, Michele, Tobinai, Kensei, Iida, Shinsuke, Chou, Takaai, Suzuki, Kenshi, Kosugi, Hiroshi, Taniwaki, Masafumi, Sunami, Kazutaka, Matsumoto, Morio, Ando, Kiyoshi, Ganly, Peter, Blacklock, Hilary, Simpson, David, George, Anupkumar, Schjesvold, Fredrik, Gjertsen, Bjorn, Lahuerta, Juan, Blade, Joan, Oriol Rocafiguera, Albert, Mateos, Maria, Rodriguez-Otero, Paula, Larson, Sarah, Atanackovic, Djordje, Devarakonda, Srinivas, Bitran, Jacob, Zonder, Jeffrey, Morganstein, Neil, Hay, Mohammad, Chanan-Khan, Asher, Saylors, Gene, Kio, Ebenezer, Oliff, Ira, Kirkel, Dean, Shtivelband, Mikhail, Yuen, Carrie, Yee, Andrew, Shah, Jatin, Htut, Myo, Raza, Shahzad, Chhabra, Saurabh, Stiff, Patrick, Hari, Parameswaran, Bank, Bruce, Malek, Ehsan, Gasparetto, Cristina, Faroun, Ycaoub, Sherbenou, Daniel, Kreisle, William, Singhal, Seema, Rosenblatt, Jacalyn, Usmani, Saad, Lee, Wes, Safah, Hana, Lutzky, Jose, Suh, Jason, Pan, Dorothy, Baron, Ari, Manges, Robert, Steis, Ronald, Oliveira, Moacyr, Moreb, Jan, Callander, Natalie, Anz, Bertrand, Raptis, Anastasios, Stampleman, Laura, Melear, Jason, Boyd, Thomas, Garbo, Lawrence, Klein, Leonard, Shao, Spencer, Lyons, Roger, McIntyre, Kristi, Tarantolo, Stefano, Yasenchak, Christopher, Yimer, Habte, Mateos, Maria-Victoria ^*, Oriol, Albert, Larocca, Alessandra, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar

Source: In The Lancet Haematology September 2019 6(9):e459-e469

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Authors: Lim, Andrew, Grigoriadis, George, Walker, Trish, Nicol, Andrew, LeBlanc, Richard, Reece, Donna, Elemary, Mohamed, Boudreault Pedneault, Jean Samuel, Karlin, Lionel, Facon, Thierry, Attal, Michel, Weisel, Katja, Engelhardt, Monika, Mackensen, Andreas, Quinn, John, Avivi, Irit, Cohen, Amos, Magen-Nativ, Hila, Benyamini, Noam, Cavo, Michele, Larocca, Alessandra, Takezako, Naoki, Suzuki, Kenshi, Kosugi, Hiroshi, Matsumoto, Morio, Iida, Shinsuke, Ishikawa, Takayuki, Kondo, Yukio, Sunami, Kazutaka, Ando, Kiyoshi, Teshima, Takanori, Chou, Takaaki, Iwasaki, Hiromi, Miki, Hirokazu, Matsumura, Itaru, Onishi, Yasushi, Izutsu, Koji, Kizaki, Masahiro, George, Anupkumar, Blacklock, Hillary, Simpson, David, Schjesvold, Fredrik, Waage, Anders, Samoilova, Olga, Nikitin, Evgeniy, Chagorova, Tatiana, McDonald, Andrew, Patel, Moosa, Oriol Rocafiguera, Albert, San Miguel Izquierdo, Jesus, Mateos, Maria, Streetly, Matthew, Forsyth, Peter, Jackson, Graham, Jenkins, Stephen, Rifkin, Robert, Yimer, Habte, McCroskey, Robert, Martincic, Danko, Tarantolo, Stefano, Larson, Sarah, Faroun, Yacoub, Vaughn, Jennifer, Baz, Rachid, Saylors, Gene, Neppalli, Amarendra, Raptis, Anastasios, Fung, Henry, Janosky, Maxwell, Stevens, Don, Coleman, Morton, Costa, Dennis, Cross, Scott, Fanning, Suzanne, Berges, Daniel Farray, Harris, Thomas, Zackon, Ira, Atanackovic, Djordje, Lee, Kelvin, Oliff, Ira, Lee, Wes, Bensinger, William, Lutzky, Jose, Baron, Ari, Hayek, Fadi, Kirschner, Eli, Bharany, Neeraj, Overton, Lindsay, Mannem, Siva, Harroff, Allyson, Jain, Sharad, Roque, Tammy, McIntyre, Kristi, Yasencha, Christopher K, Houck, William, Usmani, Saad Zafar ^*, Oriol, Albert, Rifkin, Robert M, Yimer, Habte Aragaw, McCroskey, Robert Donald, Lim, Andrew Boon Ming, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z H, Marinello, Patricia, San-Miguel, Jesus

Source: In The Lancet Haematology September 2019 6(9):e448-e458

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Authors: Ahn, Inhye E., Farooqui, Mohammed Z.H., Tian, Xin, Valdez, Janet, Sun, Clare, Soto, Susan, Lotter, Jennifer, Housel, Stephanie, Stetler-Stevenson, Maryalice, Yuan, Constance M., Maric, Irina, Calvo, Katherine R., Nierman, Pia, Hughes, Thomas E., Saba, Nakhle S., Marti, Gerald E., Pittaluga, Stefania, Herman, Sarah E.M., Niemann, Carsten U., Pedersen, Lone B., Geisler, Christian H., Childs, Richard, Aue, Georg, Wiestner, Adrian

Source: In Blood 24 May 2018 131(21):2357-2366

A perspective on shaping of advanced ceramics by electro discharge machining

Authors: Farooqui, Mohammed Naser, Patil, Nilesh G.

Source: In Procedia Manufacturing 2018 20:65-72

Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.

Authors: Huntington, Scott F., Cheng, Wendy Y., Sarpong, Eric M., Leng, Siyang, Farooqui, Mohammed Z. H., Agu, Uchechukwu Samuel, Catillon, Maryaline, Lejeune, Dominique, Downes, Nathaniel, Matay, Lisa, Duh, Mei Sheng, De Nigris, Enrico

Source: Leukemia & Lymphoma; Jul2024, Vol. 65 Issue 7, p932-942, 11p

Subject Terms: CHRONIC lymphocytic leukemia, BRUTON tyrosine kinase, LYMPHOCYTIC leukemia, LYMPHOMAS, LONGITUDINAL method

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Authors: Ahn, Inhye E. ^*, Underbayev, Chingiz ^*, Albitar, Adam, Herman, Sarah E.M., Tian, Xin, Maric, Irina, Arthur, Diane C., Wake, Laura, Pittaluga, Stefania, Yuan, Constance M., Stetler-Stevenson, Maryalice, Soto, Susan, Valdez, Janet, Nierman, Pia, Lotter, Jennifer, Xi, Liqiang, Raffeld, Mark, Farooqui, Mohammed, Albitar, Maher, Wiestner, Adrian

Source: In Blood 16 March 2017 129(11):1469-1479

Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US.

Authors: Yang, Xiaoqin, Zanardo, Enrico, Lejeune, Dominique, Nigris, Enrico De, Sarpong, Eric, Farooqui, Mohammed, Laliberté, François

Source: Oncologist; Mar2024, Vol. 29 Issue 3, pe360-e371, 12p

Subject Terms: CHRONIC lymphocytic leukemia treatment, CHRONIC lymphocytic leukemia, SCIENTIFIC observation, CANCER chemotherapy, MEDICAL care costs, RETROSPECTIVE studies, ACQUISITION of data, MEDICAL care use, HEALTH insurance reimbursement, MEDICAL records, DESCRIPTIVE statistics, FINANCIAL stress, ECONOMIC aspects of diseases, DISEASE management, IMMUNOTHERAPY, LONGITUDINAL method

Geographic Terms: UNITED States

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

Authors: Sun, Clare, Tian, Xin, Lee, Yuh Shan, Gunti, Sreenivasulu, Lipsky, Andrew, Herman, SarahE.M., Salem, Dalia, Stetler-Stevenson, Maryalice, Yuan, Constance, Kardava, Lela, Moir, Susan, Maric, Irina, Valdez, Janet, Soto, Susan, Marti, Gerald E., Farooqui, Mohammed Z., Notkins, Abner L., Wiestner, Adrian ^*, Aue, Georg ^*

Source: In Blood 5 November 2015 126(19):2213-2219

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Authors: Farooqui, Mohammed Z H, Valdez, Janet, Martyr, Sabrina, Aue, Georg, Saba, Nakhle, Niemann, Carsten U, Herman, Sarah E M, Tian, Xin, Marti, Gerald, Soto, Susan, Hughes, Thomas E, Jones, Jade, Lipsky, Andrew, Pittaluga, Stefania, Stetler-Stevenson, Maryalice, Yuan, Constance, Lee, Yuh Shan, Pedersen, Lone B, Geisler, Christian H, Calvo, Katherine R, Arthur, Diane C, Maric, Irina, Childs, Richard, Young, Neal S, Wiestner, Adrian

Source: In Lancet Oncology February 2015 16(2):169-176

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Authors: Herman, Sarah E.M., Mustafa, Rashida Z., Gyamfi, Jennifer A., Pittaluga, Stefania, Chang, Stella, Chang, Betty, Farooqui, Mohammed, Wiestner, Adrian ^*

Source: In Blood 22 May 2014 123(21):3286-3295

Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia.

Authors: Huntington, Scott F., de Nigris, Enrico, Puckett, Justin T., Kamal‐Bahl, Sachin, Farooqui, Mohammed, Ryland, Katherine, Sarpong, Eric M., Leng, Siyang, Yang, Xiaoqin, Doshi, Jalpa A.

Source: Cancer Medicine; Jan2024, Vol. 13 Issue 2, p1-6, 6p

Subject Terms: CHRONIC lymphocytic leukemia, JOINT pain, MEDICARE beneficiaries, OLDER patients, ATRIAL fibrillation